ABOUT PERTZYE® (pancrelipase) DELAYED-RELEASE CAPSULES
PERTZYE® (pancrelipase) is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.
PERTZYE is currently available in 4 color coded capsule strengths:
• 4,000 USP units of lipase; 14,375 USP units of protease; 15,125 USP units of amylase.
• 8,000 USP units of lipase; 28,750 USP units of protease; 30,250 USP units of amylase.
• 16,000 USP units of lipase; 57,500 USP units of protease; 60,500 USP units of amylase.
• 24,000 USP units of lipase; 86,250 USP units of protease; 90,750 USP units of amylase.
For more information, visit www.pertzye.com.
IMPORTANT SAFETY INFORMATION ABOUT PERTZYE
Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement. Exercise caution when doses of PERTZYE exceed 2,500 lipase units/kg body weight per meal (or greater than 10,000 lipase units/kg body weight per day).
To avoid irritation of oral mucosa, do not chew PERTZYE or retain in the mouth.
Hyperuricemia may develop. Consider monitoring uric acid levels in patients with hyperuricemia, gout, or renal impairment.
There is theoretical risk of viral transmission with all pancreatic enzyme products including PERTZYE.
Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
Most common adverse reactions (≥ 10%) are: diarrhea, dyspepsia, and cough.
Please click here to read the full Prescribing Information and Medication Guide.